The first World Gynecologic Oncology (GO) Day was launched on September 20th, 2019 by the European Society of Gynaecological Oncology (ESGO) and the European Network of Gynaecological Cancer Advocacy Groups (ENGAGe). Their mission is to raise awareness of ovarian, uterine, cervical, vulvar, and vaginal cancers. The collective term for these five types of cancer is gynaecological cancer.
With over 1.3 million women worldwide diagnosed with gynaecological cancers in 2020, it’s more important now than ever to equip them with tools and resources to promote prevention and early detection of potential cancers. Increased public awareness of gynaecological cancer prevention can ultimately lead to improved quality of life and increased survival rate of affected women. Although there are warning signs, women can learn ways to reduce their risks in ways that make sense for their personal health, as signs and symptoms are not the same for everyone. It’s important to consult your doctor to discuss your unique situation and to schedule preventative screenings.
Over the years, World GO Day has been a joint effort by various advocacy groups around the world with both in-person and virtual events including interactive activities on the World GO Day website, scientific workshops, information sessions, and sporting events involving healthcare providers, cancer survivors, and supporters.
On September 20th you may see people wearing purple ribbons or clothing to show their support. It’s the color meant to combine awareness for all gynaecological cancers in one. In the first year of the awareness day, 33 patient advocacy groups from 22 countries in Europe and Asia joined to raise awareness with sporting events and games. This also helped to create a stronger network of people and organizations who still work together year after year to provide resources to the community.
ENGAGe says their priorities and objectives are to:
SOPHiA GENETICS is proud to support the efforts of World Go Day. You can choose to join this movement by educating yourself, sharing information with others, and showing your support. For the latest World Go Day updates, follow them on Facebook, Twitter, Instagram, and YouTube.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.